These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 27024308

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.
    Torjesen I.
    BMJ; 2013 Jul 23; 347():f4678. PubMed ID: 23881948
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. By the way, doctor. My 78-year-old husband has wet macular degeneration. He is being treated with a drug called Avastin. Is that a good choice?
    Heier JS.
    Harv Health Lett; 2010 May 23; 35(7):6. PubMed ID: 20583361
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin).
    Rhodes C, Harris J, Sulston J, Spanswick C.
    J Med Ethics; 2012 Mar 23; 38(3):187-9. PubMed ID: 21947806
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
    Landa G, Amde W, Doshi V, Ali A, McGevna L, Gentile RC, Muldoon TO, Walsh JB, Rosen RB.
    Ophthalmologica; 2009 Mar 23; 223(6):370-5. PubMed ID: 19590252
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Lessons learnt inform our approach to new antivascular endothelial growth factor treatments for neovascular age-related macular degeneration.
    Wickremasinghe S, Abedi F, Sandhu SS, Guymer R.
    Clin Exp Ophthalmol; 2013 Nov 23; 41(8):723-6. PubMed ID: 24152187
    [No Abstract] [Full Text] [Related]

  • 20. GMC is criticised for refusing to disclose reasons behind its advice to support prescribing for Lucentis rather than Avastin for wet AMD.
    Cohen D.
    BMJ; 2015 Apr 13; 350():h1981. PubMed ID: 25869865
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.